Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies.

4R-Tau DaT imaging Motor reserve [18F]PI-2620 tau-PET

Journal

European journal of nuclear medicine and molecular imaging

ISSN: 1619-7089

Titre abrégé: Eur J Nucl Med Mol Imaging

Pays: Germany

ID NLM: 101140988

Informations de publication

Date de publication:
17 Feb 2024

Historique:

received: 11 07 2023

accepted: 04 02 2024

medline: 17 2 2024

pubmed: 17 2 2024

entrez: 17 2 2024

Statut: aheadofprint

Résumé

We hypothesized that severe tau burden in brain regions involved in direct or indirect pathways of the basal ganglia correlate with more severe striatal dopamine deficiency in four-repeat (4R) tauopathies. Therefore, we correlated [ Thirty-eight patients with clinically diagnosed 4R-tauopathies (21 male; 69.0 ± 8.5 years) and 15 patients with clinically diagnosed α-synucleinopathies (8 male; 66.1 ± 10.3 years) who underwent [ In patients with 4R-tauopathies, [ Tau burden in brain regions involved in dopaminergic pathways is associated with aggravated dopaminergic dysfunction in patients with clinically diagnosed primary tauopathies. The ability to sustain dopamine transmission despite tau accumulation may preserve motor function.

Identifiants

DOI: 10.1007/s00259-024-06637-6 PMID: 38366196

pubmed: 38366196

doi: 10.1007/s00259-024-06637-6

pii: 10.1007/s00259-024-06637-6

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration. Tau pathologies with exclusively “Exon10” isoforms. J Neurochem. 1999;72:1243–9. https://doi.org/10.1046/j.1471-4159.1999.0721243.x .

doi: 10.1046/j.1471-4159.1999.0721243.x pubmed: 10037497

Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246:II6–15. https://doi.org/10.1007/BF03161076 .

doi: 10.1007/BF03161076 pubmed: 10525997

Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000;33:95–130. https://doi.org/10.1016/S0165-0173(00)00019-9 .

doi: 10.1016/S0165-0173(00)00019-9 pubmed: 10967355

Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain. 2007;130:1566–76. https://doi.org/10.1093/brain/awm104 .

doi: 10.1093/brain/awm104 pubmed: 17525140

Kouri N, Murray ME, Hassan A, Rademakers R, Uitti RJ, Boeve BF, et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain. 2011;134:3264–75. https://doi.org/10.1093/brain/awr234 .

doi: 10.1093/brain/awr234 pubmed: 21933807 pmcid: 3212714

Ling H, Kovacs GG, Vonsattel JPG, Davey K, Mok KY, Hardy J, et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain. 2016;139:3237–52. https://doi.org/10.1093/brain/aww256 .

doi: 10.1093/brain/aww256 pubmed: 27797812

Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140:99–119. https://doi.org/10.1007/s00401-020-02158-2 .

doi: 10.1007/s00401-020-02158-2 pubmed: 32383020 pmcid: 7360645

Polanco JC, Scicluna BJ, Hill AF, Götz J. Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner. J Biol Chem. 2016;291:12445–66. https://doi.org/10.1074/jbc.M115.709485 .

doi: 10.1074/jbc.M115.709485 pubmed: 27030011 pmcid: 4933440

Wang Y, Balaji V, Kaniyappan S, Krüger L, Irsen S, Tepper K, et al. The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegeneration. 2017;12:5. https://doi.org/10.1186/s13024-016-0143-y .

doi: 10.1186/s13024-016-0143-y

Katsinelos T, Zeitler M, Dimou E, Karakatsani A, Müller H-M, Nachman E, et al. Unconventional secretion mediates the trans-cellular spreading of tau. Cell Rep. 2018;23:2039–55. https://doi.org/10.1016/j.celrep.2018.04.056 .

doi: 10.1016/j.celrep.2018.04.056 pubmed: 29768203

Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127:667–83. https://doi.org/10.1007/s00401-014-1254-6 .

doi: 10.1007/s00401-014-1254-6 pubmed: 24531916 pmcid: 4252866

Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19:1085–92. https://doi.org/10.1038/nn.4328 .

doi: 10.1038/nn.4328 pubmed: 27322420 pmcid: 4961585

Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with 18 F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study. J Nucl Med. 2020;61:911–9. https://doi.org/10.2967/jnumed.119.236224 .

doi: 10.2967/jnumed.119.236224 pubmed: 31712323 pmcid: 7262222

Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies. Neuron. 2021;109:42-58.e8. https://doi.org/10.1016/j.neuron.2020.09.042 .

doi: 10.1016/j.neuron.2020.09.042 pubmed: 33125873

Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18 F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408. https://doi.org/10.1001/jamaneurol.2020.2526 .

doi: 10.1001/jamaneurol.2020.2526 pubmed: 33165511

Song M, Beyer L, Kaiser L, Barthel H, van Eimeren T, Marek K, et al. Binding characteristics of [18 F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J Cereb Blood Flow Metab. 2021;41:2957–72. https://doi.org/10.1177/0271678X211018904 .

doi: 10.1177/0271678X211018904 pubmed: 34044665 pmcid: 8545042

Messerschmidt K, Barthel H, Brendel M, Scherlach C, Hoffmann K-T, Rauchmann B-S, et al. 18 F-PI-2620 Tau PET improves the imaging diagnosis of progressive supranuclear palsy. J Nucl Med. 2022;63:1754–1760. https://doi.org/10.2967/jnumed.121.262854 .

Palleis C, Brendel M, Finze A, Weidinger E, Botzel K, Danek A, et al. Cortical [(18) F]PI-2620 binding differentiates corticobasal syndrome subtypes. Mov Disord. 2021;36:2104–15. https://doi.org/10.1002/mds.28624 .

doi: 10.1002/mds.28624 pubmed: 33951244

Endo H, Tagai K, Ono M, Ikoma Y, Oyama A, Matsuoka K, et al. A machine learning–based approach to discrimination of tauopathies using [18F]PM-PBB3 PET images. Mov Disord. 2022;37:2236–46. https://doi.org/10.1002/mds.29173 .

doi: 10.1002/mds.29173 pubmed: 36054492 pmcid: 9805085

Liu F-T, Lu J-Y, Li X-Y, Liang X-N, Jiao F-Y, Ge J-J, et al. 18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2023;50:1395–1405. https://doi.org/10.1007/s00259-022-06104-0 .

doi: 10.1007/s00259-022-06104-0 pubmed: 38150017 pmcid: 10317875

Booij J, Andringa G, Rijks LJM, Vermeulen RJ, De Bruin K, Boer GJ, et al. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse. 1997;27:183–90. https://doi.org/10.1002/(SICI)1098-2396(199711)27:3%3c183::AID-SYN4%3e3.0.CO;2-9 .

doi: 10.1002/(SICI)1098-2396(199711)27:3<183::AID-SYN4>3.0.CO;2-9 pubmed: 9329154

Booij J, Speelman JD, Horstink MWIM, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic Parkinsonism from those with other forms of Parkinsonism. Eur J Nucl Med. 2001;28:266–72. https://doi.org/10.1007/s002590000460 .

doi: 10.1007/s002590000460 pubmed: 11315592

McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. The Lancet Neurology. 2007;6:305–13. https://doi.org/10.1016/S1474-4422(07)70057-1 .

doi: 10.1016/S1474-4422(07)70057-1 pubmed: 17362834

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. Mov Disord. 2017;32:853–64. https://doi.org/10.1002/mds.26987 .

doi: 10.1002/mds.26987 pubmed: 28467028 pmcid: 5516529

Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, et al. Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021;48:3872–85. https://doi.org/10.1007/s00259-021-05391-3 .

doi: 10.1007/s00259-021-05391-3 pubmed: 34021393 pmcid: 8484138

Katzdobler S, Nitschmann A, Barthel H, Bischof G, Beyer L, Marek K, et al. Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies. Eur J Nucl Med Mol Imaging. 2023;50:423–434. https://doi.org/10.1007/s00259-022-05964-w .

Huber M, Beyer L, Prix C, Schönecker S, Palleis C, Rauchmann BS, et al. Metabolic correlates of dopaminergic loss in dementia with Lewy bodies. Mov Disord. 2020;35:595–605. https://doi.org/10.1002/mds.27945 .

doi: 10.1002/mds.27945 pubmed: 31840326

Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503. https://doi.org/10.1212/WNL.0b013e31827f0fd1 .

doi: 10.1212/WNL.0b013e31827f0fd1 pubmed: 23359374 pmcid: 3590050

Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases: PSP diagnostic criteria. Mov Disord. 2014;29:1758–66. https://doi.org/10.1002/mds.26054 .

doi: 10.1002/mds.26054 pubmed: 25370486

McMillan CT, Irwin DJ, Nasrallah I, Phillips JS, Spindler M, Rascovsky K, et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:935–7. https://doi.org/10.1007/s00401-016-1640-3 .

doi: 10.1007/s00401-016-1640-3 pubmed: 27815633 pmcid: 5154298

Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:931–3. https://doi.org/10.1007/s00401-016-1618-1 .

doi: 10.1007/s00401-016-1618-1 pubmed: 27645292 pmcid: 5107140

Ghirelli A, Tosakulwong N, Weigand SD, Clark HM, Ali F, Botha H, et al. Sensitivity–specificity of tau and amyloid β positron emission tomography in frontotemporal lobar degeneration. Ann Neurol. 2020;88:1009–22. https://doi.org/10.1002/ana.25893 .

doi: 10.1002/ana.25893 pubmed: 32869362 pmcid: 7861121

Malarte M-L, Gillberg P-G, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01875-2 .

doi: 10.1038/s41380-022-01875-2 pubmed: 36447011 pmcid: 10005967

Li J, Kumar A, Langstrom B, Nordberg A, Agren H. Insight into the binding of first- and second-generation PET tracers to 4R and 3R/4R tau protofibrils. ACS Chem Neurosci. 2023;14:3528–39. https://doi.org/10.1021/acschemneuro.3c00437 .

doi: 10.1021/acschemneuro.3c00437 pubmed: 37639522

Liu F-T, Li X-Y, Lu J-Y, Wu P, Li L, Liang X-N, et al. 18F-Florzolotau tau positron emission tomography imaging in patients with multiple system atrophy–Parkinsonian subtype. Mov Disord. 2022;37:1915–23. https://doi.org/10.1002/mds.29159 .

doi: 10.1002/mds.29159 pubmed: 35861378

Calafate S, Buist A, Miskiewicz K, Vijayan V, Daneels G, de Strooper B, et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 2015;11:1176–83. https://doi.org/10.1016/j.celrep.2015.04.043 .

doi: 10.1016/j.celrep.2015.04.043 pubmed: 25981034

Boluda S, Iba M, Zhang B, Raible KM, Lee VMY, Trojanowski JQ. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains. Acta Neuropathol. 2015;129:221–37. https://doi.org/10.1007/s00401-014-1373-0 .

doi: 10.1007/s00401-014-1373-0 pubmed: 25534024

Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of cell-to-cell transmission of pathological tau: a review. JAMA Neurol. 2019;76:101. https://doi.org/10.1001/jamaneurol.2018.2505 .

doi: 10.1001/jamaneurol.2018.2505 pubmed: 30193298 pmcid: 6382549

Franzmeier N, Brendel M, Beyer L, Slemann L, Kovacs GG, Arzberger T, et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat Commun. 2022;13:1362. https://doi.org/10.1038/s41467-022-28896-3 .

doi: 10.1038/s41467-022-28896-3 pubmed: 35292638 pmcid: 8924216

Whitwell JL, Lowe VJ, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG, et al. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy: Tau-pet in progressive supranuclear palsy. Mov Disord. 2017;32:124–33. https://doi.org/10.1002/mds.26834 .

doi: 10.1002/mds.26834 pubmed: 27787958

Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, et al. [18F]-THK5351 PET Correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2018;9:440. https://doi.org/10.3389/fnagi.2017.00440 .

doi: 10.3389/fnagi.2017.00440 pubmed: 29387005 pmcid: 5776329

Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. The Lancet Neurology. 2012;11:1006–12. https://doi.org/10.1016/S1474-4422(12)70191-6 .

doi: 10.1016/S1474-4422(12)70191-6 pubmed: 23079557 pmcid: 3507991

Soldan A, Pettigrew C, Cai Q, Wang J, Wang M-C, Moghekar A, et al. Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer’s disease. Neurobiol Aging. 2017;60:164–72. https://doi.org/10.1016/j.neurobiolaging.2017.09.002 .

doi: 10.1016/j.neurobiolaging.2017.09.002 pubmed: 28968586 pmcid: 5679465

Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, Belleville S, Cantilon M, Chetelat G, et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2020;16:1305–11. https://doi.org/10.1016/j.jalz.2018.07.219 .

doi: 10.1016/j.jalz.2018.07.219 pubmed: 30222945

Hoenig MC, Dzialas V, Drzezga A, van Eimeren T. The concept of motor reserve in Parkinson’s disease: new wine in old bottles? Mov Disord. 2022;38:16–20. https://doi.org/10.1002/mds.29266 .

Kaindlstorfer C, Jellinger KA, Eschlbock S, Stefanova N, Weiss G, Wenning GK. The relevance of iron in the pathogenesis of multiple system atrophy: a viewpoint. J Alzheimers Dis. 2018;61:1253–73. https://doi.org/10.3233/JAD-170601 .

doi: 10.3233/JAD-170601 pubmed: 29376857 pmcid: 5798525

Lee S, Martinez-Valbuena I, de Andrea CE, Villalba-Esparza M, Ilaalagan S, Couto B, et al. Cell-specific dysregulation of iron and oxygen homeostasis as a novel pathophysiology in PSP. Ann Neurol. 2023;93:431–45. https://doi.org/10.1002/ana.26540 .

doi: 10.1002/ana.26540 pubmed: 36309960

Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13:1045–60. https://doi.org/10.1016/S1474-4422(14)70117-6 .

doi: 10.1016/S1474-4422(14)70117-6 pubmed: 25231526 pmcid: 5672917

Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann Neurol. 1992;32:94–100. https://doi.org/10.1002/ana.410320716 .

doi: 10.1002/ana.410320716

Lee JH, Lee MS. Brain iron accumulation in atypical Parkinsonian syndromes: in vivo MRI evidences for distinctive patterns. Front Neurol. 2019;10:74. https://doi.org/10.3389/fneur.2019.00074 .

doi: 10.3389/fneur.2019.00074 pubmed: 30809185 pmcid: 6379317

Lee SH, Lyoo CH, Ahn SJ, Rinne JO, Lee MS. Brain regional iron contents in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;45:28–32. https://doi.org/10.1016/j.parkreldis.2017.09.020 .

doi: 10.1016/j.parkreldis.2017.09.020 pubmed: 28982612

Duce JA, Wong BX, Durham H, Devedjian JC, Smith DP, Devos D. Post translational changes to alpha-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease. Mol Neurodegener. 2017;12:45. https://doi.org/10.1186/s13024-017-0186-8 .

doi: 10.1186/s13024-017-0186-8 pubmed: 28592304 pmcid: 5463308

Han J, Fan Y, Wu P, Huang Z, Li X, Zhao L, et al. Parkinson’s disease dementia: synergistic effects of alpha-synuclein, tau, beta-amyloid, and iron. Front Aging Neurosci. 2021;13:743754. https://doi.org/10.3389/fnagi.2021.743754 .

doi: 10.3389/fnagi.2021.743754 pubmed: 34707492 pmcid: 8542689

Wise RM, Wagener A, Fietzek UM, Klopstock T, Mosharov EV, Zucca FA, et al. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson’s disease and neurodegeneration with brain iron accumulation disorders. Neurobiol Dis. 2022;175:105920. https://doi.org/10.1016/j.nbd.2022.105920 .

doi: 10.1016/j.nbd.2022.105920 pubmed: 36351559

Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology. 2017;88:1461–7. https://doi.org/10.1212/WNL.0000000000003810 .

doi: 10.1212/WNL.0000000000003810 pubmed: 28283599

Colloby SJ, McParland S, O’Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain. 2012;135:2798–808. https://doi.org/10.1093/brain/aws211 .

doi: 10.1093/brain/aws211 pubmed: 22961551

Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts: correlation of DAT imaging with SN cell counts. Mov Disord. 2014;29:1767–73. https://doi.org/10.1002/mds.25975 .

doi: 10.1002/mds.25975 pubmed: 25048738

Choi JY, Cho H, Ahn SJ, Lee JH, Ryu YH, Lee MS, et al. Off-target (18)F-AV-1451 binding in the basal ganglia correlates with age-related iron accumulation. J Nucl Med. 2018;59:117–20. https://doi.org/10.2967/jnumed.117.195248 .

doi: 10.2967/jnumed.117.195248 pubmed: 28775201

Marquie M, Verwer EE, Meltzer AC, Kim SJW, Aguero C, Gonzalez J, et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case. Acta Neuropathol Commun. 2017;5:75. https://doi.org/10.1186/s40478-017-0482-0 .

doi: 10.1186/s40478-017-0482-0 pubmed: 29047416 pmcid: 5648451

Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408–19. https://doi.org/10.1001/jamaneurol.2020.2526 .

doi: 10.1001/jamaneurol.2020.2526 pubmed: 33165511

Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, et al. Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46:2178–89. https://doi.org/10.1007/s00259-019-04397-2 .

doi: 10.1007/s00259-019-04397-2 pubmed: 31264169 pmcid: 6667408

Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022;63:20S-S26. https://doi.org/10.2967/jnumed.121.263196 .

doi: 10.2967/jnumed.121.263196 pubmed: 35649647

Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement (Amst). 2018;10:232–6. https://doi.org/10.1016/j.dadm.2018.01.007 .

doi: 10.1016/j.dadm.2018.01.007 pubmed: 29780868

Kroth H, Oden F, Serra AM, Molette J, Mueller A, Berndt M, et al. Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core. Bioorg Med Chem. 2021;52:116528. https://doi.org/10.1016/j.bmc.2021.116528 .

doi: 10.1016/j.bmc.2021.116528 pubmed: 34839158

Kunze G, Kumpfel R, Rullmann M, Barthel H, Brendel M, Patt M, et al. Molecular simulations reveal distinct energetic and kinetic binding properties of [(18)F]PI-2620 on tau filaments from 3R/4R and 4R tauopathies. ACS Chem Neurosci. 2022;13:2222–34. https://doi.org/10.1021/acschemneuro.2c00291 .

doi: 10.1021/acschemneuro.2c00291 pubmed: 35762647

McFarland NR. Diagnostic approach to atypical Parkinsonian syndromes. Continuum (Minneap Minn). 2016;22:1117–42. https://doi.org/10.1212/CON.0000000000000348 .

doi: 10.1212/CON.0000000000000348 pubmed: 27495201